Exagen $XGN fell about 23% after Q3 even though revenue grew 7% to $18.4M, slightly above estimates. The real problem: AVISE CTD test volume rose only 2%, down

Exagen $XGN fell about 23% after Q3 even though revenue grew 7% to $18.4M, slightly above estimates. The real problem: AVISE CTD test volume rose only 2%, down sharply from double-digit growth earlier in 2026, and the per-share loss of $0.25 was wider than the roughly $0.19 expected. Growth is now …